Avita Medical RCEL 深 沪
等待开盘 10-07 09:30:00 美东时间
12.89
-0.360
-2.72%
华盛通- 最 高13.495
- 今 开13.38
- 成交量 28.45万股
- 最 低 9.60
- 昨 收 13.25
- 总市值 32.17万
- 52周最高 13.495
- 市盈率 静 --
- 换手率 1140.21%
- 52周最低 3.22
- 委 比 -89.95%
- 总股本 2.50万
- 历史最高 49.11
- 量 比 1.06
- 振 幅 29.40%
- 历史最低 1.10
- 每 手 1
- 风险率 2.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
BTIG Upgrades AVITA Medical to Neutral
BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Sell to Neutral.
2025-11-20 20:14
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
AVITA Medical任命临时首席执行官
专注于皮肤修复设备及自体细胞疗法的开发和商业化企业AVITA Medical（RCEL）股价暴跌27.2%。该公司在董事会决定后，已任命Cary Vance为临时首席执行官。此外该公司正在重新讨论与OrbiMed的未来契约条款，并预计2025年收入在7600万至8100万美元之间。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-10-17 23:42
再生医学公司Avita Medical公司（RCEL）股价飙升35%
美股周一早盘，再生医学公司Avita Medical公司（RCEL）股价飙升35%，此前其RECELL GO设备获得CE认证，推动股价上涨10%。该设备有助于治疗急性创伤损伤，并扩大Avita在欧洲医疗市场的业务范围。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-09-15 22:58
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
<p>Study highlights that AVITA Medical's RECELL technology reduces hospital stays and costs for burn patients, offering a more efficient and less painful alternative to traditional skin grafts.</p>
2025-06-09 13:00
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™
AVITA Medical's Cohealyx™, a collagen-based dermal matrix, shows faster wound bed vascularization and autograft readiness (5-10 days vs. 2-4 weeks) in a case series, published in the *Journal of Surgery*. Patients achieved excellent skin graft outcomes, highlighting potential for earlier wound closure and reduced complications. The study validates preclinical findings, positioning Cohealyx as a significant advancement in wound management.
2025-06-05 20:04
AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards
AVITA Medical’s RECELL system, recognized as the 2025 MedTech Breakthrough Award winner for Best New Technology Solution in Surgical, has treated over 30,000 patients globally for thermal burn wounds and skin defects. The system reduces donor skin requirements, accelerates recovery, and improves clinical outcomes, while maintaining high procedural consistency.
2025-06-04 00:00
